{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-027034","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.102929+00:00","generated_at":"2026-06-10T08:02:14.737226+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO subsidiary ModeX awarded $59M BARDA contract for multispecific antibody against SARS-CoV-2, up to $168M total","bullets":["ModeX (OPKO subsidiary) received initial $59M from BARDA for MSTAR multispecific antibody Phase 1 trial against SARS-CoV-2.","Up to $109M additional contingent on milestones for developing antibodies against influenza and other viral pathogens.","Total potential contract value $168M; part of HHS' Project NextGen for innovative COVID-19 vaccines and therapeutics.","Gene-based delivery methods (mRNA/DNA vectors) will be developed to leverage body's natural protein production.","In March 2023, ModeX entered exclusive worldwide license with Merck for Epstein-Barr virus vaccine candidate MDX2201."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-027034","json":"https://secwatch.observer/filing/0001437749-23-027034.json","markdown":"https://secwatch.observer/filing/0001437749-23-027034.md","text":"https://secwatch.observer/filing/0001437749-23-027034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774923027034/0001437749-23-027034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774923027034/opk20230928c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:02:14.737226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}